107 studies found for:    Empagliflozin
Show Display Options
Rank Status Study
1 Completed
Has Results
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers
Condition: Healthy
Interventions: Drug: 5 mg empagliflozin/850 mg metformin FDC;   Drug: 12.5 mg empagliflozin;   Drug: 850 mg metformin;   Drug: 5 mg empagliflozin;   Drug: 12.5 mg empagliflozin/850 mg metformin FDC;   Drug: 12.5 mg empagliflozin/500 mg metformin FDC;   Drug: 5 mg empagliflozin/500 mg metformin FDC;   Drug: 500 mg metformin
2 Not yet recruiting Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
Condition: Diabetes Mellitus, Type II
Interventions: Drug: Empagliflozin 25mg;   Drug: Lobeglitazone 0.5mg;   Drug: Empagliflozin 25mg/Lobeglitazone 0.5mg
3 Active, not recruiting Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Empagliflozin;   Drug: Placebo
4 Completed
Has Results
Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
Condition: Healthy
Interventions: Drug: empagliflozin;   Drug: metformin (Glucophage®);   Drug: empagliflozin and metformin
5 Completed
Has Results
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Empagliflozin medium placebo;   Drug: Empagliflozin low placebo;   Drug: Empagliflozin high placebo;   Drug: Empagliflozin medium;   Drug: Empagliflozin low;   Drug: Empagliflozin high
6 Completed
Has Results
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Condition: Healthy
Interventions: Drug: Empagliflozin;   Drug: Metformin;   Drug: Empagliflozin/Metformin
7 Completed
Has Results
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
Condition: Healthy
Interventions: Drug: BI 10773/linagliptin;   Drug: BI 10773/linagliptin SID;   Drug: BI 10773/linagliptin FDC
8 Completed Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Linagliptin;   Other: Placebo;   Drug: Empagliflozin
9 Recruiting Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Condition: Non Alcoholic Fatty Liver Disease
Intervention: Drug: Empagliflozin
10 Recruiting Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Empagliflozin and Linagliptin;   Drug: Metformin and Insulin sc
11 Completed
Has Results
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions: Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin low dose qd;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Empagliflozin high dose bid
12 Completed Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
Condition: Healthy
Interventions: Drug: metformin;   Drug: empagliflozin/metformin;   Drug: empagliflozin
13 Completed Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
Condition: Healthy
Interventions: Drug: metformin;   Drug: empagliflozin/metformin;   Drug: empagliflozin
14 Completed
Has Results
Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BI 10773 25 mg;   Drug: Warfarin 25 mg;   Drug: Warfarin
15 Completed
Has Results
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: empagliflozin (low dose qd);   Drug: Empagliflozin (high dose qd);   Drug: empagliflozin (high dose bid);   Drug: empagliflozin (low dose bid)
16 Active, not recruiting Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
17 Recruiting Empagliflozin and ACEi Effects on Hyperfiltration in Type 1 Diabetes (BETWEEN Study)
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Empagliflozin;   Drug: Placebo (matching empagliflozin);   Drug: ramipril
18 Completed Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets
Condition: Healthy
Interventions: Drug: Empagliflozin/Metformin XR, FDC;   Drug: Empagliflozin/Metformin XR FDC;   Drug: 25 mg Empafliglozin/1000 mg Metformin XR, FDC;   Drug: 1 tablet Empagliflozin/2 tablets Metformin XR;   Drug: 1 tablet Empagliflozin/3 tablets Metformin XR
19 Completed
Has Results
Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
Condition: Healthy
Interventions: Drug: Probenecid;   Drug: Rifampicin;   Drug: Empagliflozin;   Drug: Empagliflozin (BI 10773)
20 Completed
Has Results
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years